Related Experiment Video
Updated: Dec 30, 2025

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis
Published on: March 24, 2017
Collocating Novel Targets for Tuberculosis (TB) Drug Discovery
1Faculty of Pharmacy, Ramanbhai Patel College of Pharmacy, Charotar University of Science and Technology, Charusat campus, Changa, Gujarat, India.
Advanced genetic and molecular approaches are crucial for combating drug-resistant Tuberculosis (TB). This review highlights key targets and novel compounds for developing effective TB diagnostics and therapies.
Area of Science:
- Molecular biology
- Genetics
- Drug discovery
Background:
- Mycobacterium tuberculosis poses a global health threat due to increasing multi-drug resistant (MDR) and extensively drug-resistant (XDR) strains.
- Current treatment strategies are challenged by bacterial resistance, necessitating novel therapeutic approaches.
Purpose of the Study:
- To review genetic and molecular targets for Tuberculosis (TB) drug discovery.
- To identify promising biomarkers and therapeutic compounds for TB treatment.
Main Methods:
- Literature review focused on TB drug discovery.
- Analysis of genetic mutations and molecular targets in TB.
- Evaluation of novel chemical scaffolds and their therapeutic potential.
Main Results:
- Identified key genetic expressions like Bhlhe40, NRAMP1, and VDR impacting TB.
- Discussed novel compounds including imidazopyridine amine derivative (Q203) and biphenyl amide derivative (DG70).
- Highlighted therapeutic potential of azetidine, thioquinazole, tetrahydroindazole, and 2-mercapto-quinazoline scaffolds against targets like ATP and fatty acid synthesis.
Conclusions:
- Genetic and molecular insights are vital for overcoming TB resistance.
- Novel compounds and targets show promise for future TB drug development.
More Related Videos
09:57System for Efficacy and Cytotoxicity Screening of Inhibitors Targeting Intracellular Mycobacterium tuberculosis
Published on: April 5, 2017
15:28A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening
Published on: January 17, 2014
Related Concept Videos
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Drug Discovery: Overview
Pulmonary Tuberculosis IV
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis II
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...